STOCK TITAN

SS Innovations International (SSII) Stock Price, News & Analysis

SSII NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
67 252 sessions, October 2, 2025 to October 2, 2026
Largest daily move
+34.5% close of October 14, 2025
1-year change
-58.9% closing prices, October 2, 2025 to October 2, 2026
1-month change
-21.5% closing prices, September 2, 2026 to October 2, 2026

Company Description

SS Innovations International Inc. (Nasdaq: SSII) is a commercial-stage surgical robotics company that develops surgical robotic technologies with a stated vision of making the benefits of robotic surgery more affordable and accessible to a larger segment of the global population. The company is described as an American company headquartered in India and its shares are listed on The Nasdaq Stock Market LLC under the symbol SSII.

According to company disclosures, SS Innovations focuses on designing, manufacturing, and marketing advanced, next-generation surgical robotic systems and related instruments. Its primary product is the proprietary SSi Mantra surgical robotic system, which is characterized as a user-friendly, modular, multi-arm platform. The SSi Mantra is described as having 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, and a touch panel monitor for displaying patient-related information. The system also incorporates virtual real-time visualization of the robotic patient-side arm carts and the ability to superimpose 3D models of diagnostic imaging.

SS Innovations reports that a vision cart associated with the SSi Mantra provides the table-side team with the same magnified 3D 4K view as the surgeon, which the company states is intended to support safety and efficiency in the operating room. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery. Company materials further state that the SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures.

Core products and technologies

SS Innovations highlights two main product families in its public communications:

  • SSi Mantra surgical robotic system – a modular, multi-arm robotic platform with an open-faced surgeon command center, 3D 4K visualization, touch panel interface, and capabilities for virtual real-time views of patient-side carts and superimposition of 3D diagnostic imaging models. The company notes that the system supports a variety of robotically assisted soft-tissue surgeries and has been used in areas such as cardiac surgery.
  • SSi Mudra surgical instruments – a comprehensive suite of surgical instruments designed to work with the SSi Mantra system. Company descriptions state that these instruments support a variety of robotic surgical procedures, including cardiac surgery.

In addition, SS Innovations has publicly discussed the SSi Mantra Tele Surgeon Console (TSC), described as a compact, self-contained chair-based version of the larger SSi Mantra surgeon command center. According to company statements, the TSC is designed to enable portability, require less space, and facilitate telesurgeries from a range of settings, including physician offices, provided connectivity is available.

Clinical use and procedure types

Company news releases indicate that the SSi Mantra system has been used in multiple surgical specialties. SS Innovations states that the platform supports procedures in general surgery, urology, colorectal surgery, gynecology, and cardiac surgery. The company has also highlighted use in pediatric procedures and head and neck surgery, particularly in connection with the development of smaller instruments.

SS Innovations reports that the SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures. Public disclosures also reference the use of the system in robotic cardiac surgery and in telesurgery applications, including pediatric and cardiac procedures, as well as other categories such as urology, gynecology, oncology, and general surgery.

Instruments and pediatric-focused developments

In its communications, SS Innovations has described the development of multiple 5-millimeter surgical instruments intended for use with the SSi Mantra system. The company lists these instruments as including a spatula cautery, hook cautery, needle driver, bipolar forceps, and grasping forceps. According to the company, these smaller instruments are designed for clinical use across multiple specialties, including pediatric, cardiac, and head and neck surgery, and for procedures involving smaller anatomical structures.

Company commentary links these 5-millimeter instruments to the goal of supporting large, underserved patient segments, particularly pediatric patients and cardiac surgery cases where small structures are involved. SS Innovations states that it intends to continue focusing on developing differentiated surgical robotic technologies, including such instruments, for the benefit of a larger segment of patients globally.

Telesurgery capabilities

SS Innovations has publicly emphasized the telesurgery capabilities of the SSi Mantra platform. The company has announced the successful completion of telesurgeries performed using the SSi Mantra system and the SSi Mantra Tele Surgeon Console. These disclosures include references to robotic telesurgeries performed over substantial distances, including pediatric pyeloplasty telesurgery and coronary artery bypass procedures.

According to company statements, the Tele Surgeon Console incorporates inbuilt electronics, lightweight glasses with magnified three-dimensional view capabilities, and magnetic sensor-based controls. SS Innovations indicates that the TSC’s smaller footprint compared to the standard surgeon command center is intended to allow hospital networks to place consoles in the offices of surgical experts without dedicating entire operating rooms, subject to connectivity.

Geographic footprint and regulatory context

SS Innovations describes itself as an American company headquartered in India and has stated in multiple communications that it plans to expand the global presence of its surgical robotic solutions. Company news releases reference regulatory approvals for the SSi Mantra system in several countries and describe installations across multiple countries outside India, although specific country names beyond India are not detailed in the provided materials.

The company has discussed its efforts to obtain regulatory clearance in the United States and the European Union. SS Innovations has reported the completion of a human factors validation study for the SSi Mantra at Johns Hopkins Hospital, which it states is intended to support a 510(k) premarket notification submission to the U.S. Food and Drug Administration (FDA) for multiple specialty indications. The company has also indicated that it is pursuing European Union CE marking certification for the SSi Mantra.

Business model indications

Based on company statements, SS Innovations’ activities include the design, manufacture, and marketing of surgical robotic systems and associated instruments and accessories. Publicly reported financial information indicates that the company generates revenue from system sales, instrument sales, warranty sales, and lease income related to its SSi Mantra systems and instruments. These disclosures suggest a business model centered on the sale and support of surgical robotic platforms and their associated instruments.

Stock information and corporate structure

According to its SEC filings, SS Innovations International Inc. is incorporated in Florida and has common stock registered under Section 12(b) of the Securities Exchange Act of 1934. The company’s common stock trades on The Nasdaq Stock Market LLC under the ticker symbol SSII. SEC filings also indicate that the company has authorized preferred stock and common stock, and that it files periodic and current reports, including Form 10-Q and Form 8-K, with the U.S. Securities and Exchange Commission.

Position within surgical robotics

SS Innovations’ public materials consistently describe a focus on making robotic surgery more affordable and accessible to a broader global population, including underserved communities and pediatric patients. The company emphasizes cost-effective design, user-friendly interfaces, and multi-specialty capabilities for its SSi Mantra system, along with telesurgery features intended to extend surgical expertise over distance.

Company communications also highlight the clinical experience accumulated with the SSi Mantra system, including thousands of surgical procedures and numerous telesurgeries, as well as its use in cardiac and pediatric cases. These elements form a central part of SS Innovations’ stated value proposition in the surgical robotics field.

FAQs about SS Innovations International Inc. (SSII)

  • What does SS Innovations International Inc. do?

    SS Innovations International Inc. develops surgical robotic technologies. The company designs, manufactures, and markets the SSi Mantra surgical robotic system and associated SSi Mudra surgical instruments, which are used to perform a variety of robotically assisted soft-tissue surgeries, including cardiac procedures.

  • What is the SSi Mantra surgical robotic system?

    The SSi Mantra is a modular, multi-arm surgical robotic system described by the company as user-friendly and technologically advanced. It features 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for patient information, and capabilities for virtual real-time visualization of patient-side carts and superimposition of 3D diagnostic imaging models.

  • Which surgical specialties does the SSi Mantra support?

    Company disclosures state that the SSi Mantra supports multiple specialties, including general surgery, urological, colorectal, gynecological, and cardiac surgery. SS Innovations has also referenced use in pediatric and head and neck procedures, particularly in connection with smaller 5-millimeter instruments.

  • What are SSi Mudra surgical instruments?

    SSi Mudra refers to a suite of surgical instruments designed for use with the SSi Mantra surgical robotic system. According to the company, these instruments support a variety of robotic surgical procedures, including cardiac surgery, and form part of the overall product range offered by SS Innovations.

  • How has the SSi Mantra been used clinically?

    SS Innovations reports that the SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures. Company communications also reference thousands of surgeries performed using the system, including cardiac procedures and telesurgeries across several categories such as pediatric, urology, gynecology, oncology, and general surgery.

  • What is the SSi Mantra Tele Surgeon Console (TSC)?

    The SSi Mantra Tele Surgeon Console is described by SS Innovations as a compact, self-contained chair-based version of the standard SSi Mantra surgeon command center. It is intended to enable telesurgeries from various locations, including physician offices, by combining inbuilt electronics, lightweight glasses with magnified three-dimensional viewing, and magnetic sensor-based controls, subject to connectivity.

  • Where is SS Innovations headquartered?

    Company descriptions state that SS Innovations International Inc. is an American company headquartered in India. Its SEC filings list a principal executive office in Gurugram, Haryana, India, while the company is incorporated in Florida.

  • On which exchange does SS Innovations trade and what is its ticker?

    According to SEC filings, SS Innovations International Inc.’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on The Nasdaq Stock Market LLC under the ticker symbol SSII.

  • How does SS Innovations describe its mission?

    In its public communications, SS Innovations states that its vision is to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. This includes a focus on underserved patient communities and pediatric patients, as well as efforts to expand the global presence of its surgical robotic solutions.

  • What revenue sources does SS Innovations report?

    In its financial disclosures, SS Innovations reports revenue from system sales, instrument sales, warranty sales, and lease income. These revenue categories relate to the SSi Mantra surgical robotic system and associated instruments and services.

Stock Performance

$2.65
-3.64%
0.10
Last updated: October 2, 2026 at 16:48
-58.9%
Performance 1 year
$531.0M

SS Innovations International (SSII) closed at $2.67 on October 2, 2026. Over the past 12 months, the price has lost 58.9%.

See what a $1,000 investment in SSII would be worth today

SSII Metrics & Rankings

Price returns through October 2, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
33,333
Shares Sold
1
Transactions
Most Recent Transaction
Sudhir Srivastava (Chairman and CEO) sold 33,333 shares @ $3.00 on September 4, 2026

Insider selling at SS Innovations International over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

SS Innovations International generated $42.5M in revenue in FY2025, retaining a 46.0% gross margin, operating income reached -$8.2M (-19.3% operating margin), and net income was -$12.1M, reflecting a -28.5% net profit margin. Diluted earnings per share stood at -$0.06. The company generated -$18.5M in operating cash flow. The current ratio was 1.86, measuring current assets divided by current liabilities.

$42.5M
Revenue (FY2025)
-$12.1M
Net Income (FY2025)
-$18.5M
Operating Cash Flow

Upcoming Events

DEC
31
December 31, 2026 Regulatory

EU CE marking

SS Innovations expects CE marking for the SSi Mantra by end of 2026, enabling expanded commercial access in EU markets.
JAN
01
January 1, 2027 - March 31, 2027 Regulatory

FDA 510(k) decision

SS Innovations expects completion of FDA 510(k) review for the SSi Mantra during Q1 2027, critical for US commercialization.
JAN
01
January 1, 2027 - March 31, 2027 Regulatory

FDA 510(k) decision

SS Innovations expects FDA review of its 510(k) submission to complete by end of Q1 2027; potential US market impact.
MAR
06
March 6, 2031 Financial

Five-year warrant expiry

Five-year warrants issued in the Mar 6, 2026 private placement expire; potential dilution risk

SS Innovations International has 4 upcoming scheduled events. The next event, "EU CE marking", is scheduled for December 31, 2026 (in 86 days). 1 of the upcoming events are financial in nature, such as earnings calls or quarterly results. Investors can track these dates to stay informed about potential catalysts that may affect the SSII stock price.

Short Interest History

Last 12 Months

Short interest in SS Innovations International (SSII) currently stands at 59.7 thousand shares, down 18.4% from the previous reporting period, representing 0.1% of the float. Since October 2025, short interest has decreased by 62.7%.

Days to Cover History

Last 12 Months

Days to cover for SS Innovations International (SSII) currently stands at 1.0 days, down 47.6% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 1.0 to 4.2 days.

SSII Company Profile & Sector Positioning

SS Innovations International (SSII) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing SSII often look at related companies in the same sector, including Integra LifeSciences Holdings (IART), AdaptHealth Corp. (AHCO), NovoCure Limited (NVCR), Beta Bionics, Inc. (BBNX), and Establishment Labs Holdings Inc. (ESTA). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate SSII's relative position within its industry.

Frequently Asked Questions

What is the current stock price of SS Innovations International (SSII)?

The current stock price of SS Innovations International (SSII) is $2.65 as of October 2, 2026.

What is the market cap of SS Innovations International (SSII)?

The market cap of SS Innovations International (SSII) is approximately $531.0M. Learn more about what market capitalization means .

What is the revenue of SS Innovations International (SSII) stock?

The FY2025 revenue of SS Innovations International (SSII) is $42.5M, from its most recent completed fiscal year.

What is the net income of SS Innovations International (SSII)?

The FY2025 net income of SS Innovations International (SSII) is -$12.1M, from its most recent completed fiscal year.

What is the earnings per share (EPS) of SS Innovations International (SSII)?

The diluted earnings per share (EPS) of SS Innovations International (SSII) is -$0.06 for FY2025, its most recent completed fiscal year. Learn more about EPS .

What is the operating cash flow of SS Innovations International (SSII)?

The operating cash flow of SS Innovations International (SSII) is -$18.5M. Learn about cash flow.

What is the profit margin of SS Innovations International (SSII)?

The net profit margin of SS Innovations International (SSII) is -28.5%. Learn about profit margins.

What is the operating margin of SS Innovations International (SSII)?

The operating profit margin of SS Innovations International (SSII) is -19.3%. Learn about operating margins.

What is the gross margin of SS Innovations International (SSII)?

The gross profit margin of SS Innovations International (SSII) is 46.0%. Learn about gross margins.

What is the current ratio of SS Innovations International (SSII)?

The current ratio of SS Innovations International (SSII) is 1.86, measuring current assets divided by current liabilities. Learn about liquidity ratios.

What is the gross profit of SS Innovations International (SSII)?

The gross profit of SS Innovations International (SSII) is $19.5M for FY2025, its most recent completed fiscal year.

What is the operating income of SS Innovations International (SSII)?

The operating income of SS Innovations International (SSII) is -$8.2M. Learn about operating income.